Impact of single nucleotide polymorphisms (R132Q and W120R) on the binding affinity and metabolic activity of CYP2C19 toward some therapeutically important substrates

References

• Attia TZ, Yamashita T, Hammad MA, et al. (2014). Effect of cytochrome P450 2C19 and 2C9 amino acid residues 72 and 241 on metabolism of tricyclic antidepressant drugs. Chem Pharm Bull 62:176–81.
   PubMed Web of Science ®Google Scholar
• Attia TZ, Yamashita T, Miyamoto M, et al. (2012). Comparison of cytochrome P450 mediated metabolism of three central nervous system acting drugs. Chem Pharm Bull 60:1544–9.
   PubMed Web of Science ®Google Scholar
• Baumann P, Jonzier-Perey M, Koeb L, et al. (1986). Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1:102–12.
   PubMed Web of Science ®Google Scholar
• Bernhardt R, Pommerening K, Ruckpaul K. (1987). Modification of carboxyl groups on NADPH-cytochrome P-450 reductase involved in binding of cytochromes c and P-450 LM2. Biochem Int 14:823–32.
   PubMedGoogle Scholar
• Bousquet-Mélou A, Laffont CM, Laroute V, Toutain PL. (2002). Modelling the loss of metabolic capacities of cultured hepatocytes: application to measurement of Michaelis-Menten kinetic parameters in in vitro systems. Xenobiotica 32:895–906.
   PubMed Web of Science ®Google Scholar
• Bridges A, Gruenke L, Chang YT, et al. (1998). Identification of the binding site on cytochrome P450 2B4 for cytochrome b5 and cytochrome P450 reductase. J Biol Chem 273:17036–49.
   PubMed Web of Science ®Google Scholar
• De Morais S, Wilkinson GR, Blaisdell J, et al. (1994a). Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–8.
   PubMed Web of Science ®Google Scholar
• De Morais S, Wilkinson GR, Blaisdell J, et al. (1994b). The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419–22.
   PubMed Web of Science ®Google Scholar
• Derayea SM, Tsujino H, Oyama Y, et al. (2019). Investigation on drug-binding in heme pocket of CYP2C19 with UV-visible and resonance Raman spectroscopies. Spectrochim Acta A Mol Biomol Spectrosc 209:209–16.
   PubMed Web of Science ®Google Scholar
• Evans WE, McLeod HL. (2003). Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348:538–49.
   PubMed Web of Science ®Google Scholar
• Frere C, Cuisset T, Gaborit B, et al. (2009). The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost 7:1409–11.
   PubMed Web of Science ®Google Scholar
• Goldstein JA, de Morais SM. (1994). Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285–99.
   PubMedGoogle Scholar
• Gonzalez FJ, Nebert DW. (1990). Evolution of the P450 gene superfamily: animal-plant ‘warfare’, molecular drive and human genetic differences in drug oxidation. Trends Genet 6:182–6.
   PubMed Web of Science ®Google Scholar
• Gotoh O. (1992). Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83–90.
   PubMed Web of Science ®Google Scholar
• Ibeanu GC, Blaisdell J, Ferguson RJ, et al. (1999). A novel transversion in the intron 5 donor splice function ofCYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drugS-mephenytoin. J Pharmacol Exp Ther 290:635–40.
   PubMed Web of Science ®Google Scholar
• Ibeanu GC, Blaisdell J, Ghanayem BI, et al. (1998a). An additional defective allele, CYP2C19* 5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 8:129–35.
   PubMedGoogle Scholar
• Ibeanu GC, Goldstein JA, Meyer U, et al. (1998b). Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 286:1490–5.
   PubMed Web of Science ®Google Scholar
• Imai Y, Sato R. (1966). Substrate interaction with hydroxylase system in liver microsomes. Biochem Biophys Res Commun 22:620–6.
   PubMed Web of Science ®Google Scholar
• Inano H, Tamaoki BI. (1985). The presence of essential carboxyl group for binding of cytochrome c in rat hepatic Nadph-cytochrome P-450 reductase by the reaction with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. J Enzym Inhib 1:47–59.
   PubMedGoogle Scholar
• Ingelman-Sundberg M. (2004). Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25:193–200.
   PubMed Web of Science ®Google Scholar
• Koyama E, Chiba K, Tani M, Ishizaki T. (1997). Reappraisal of Human CYP Isoforms Involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 281:1199–210.
   PubMed Web of Science ®Google Scholar
• Kozyra M, Ingelman‐Sundberg M, Lauschke VM. (2017). Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med 19:20–9.
   PubMed Web of Science ®Google Scholar
• Lee M, Borgiani P, Johansson I, et al. (2014). High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase. Pharmacogenom J 14:343–9.
   PubMed Web of Science ®Google Scholar
• Li XQ, Andersson TB, Ahlstrom M, Weidolf L. (2004). Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32:821–7.
   PubMed Web of Science ®Google Scholar
• Morita J, Kobayashi K, Wanibuchi A, et al. (2004). A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylation. Drug Metab Pharmacokinet 19:236–8.
   PubMedGoogle Scholar
• Nadler SG, Strobel HW. (1991). Identification and characterization of an NADPH-cytochrome P450 reductase derived peptide involved in binding to cytochrome P450. Arch Biochem Biophys 290:277–84.
   PubMed Web of Science ®Google Scholar
• Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. (1996). Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805–16.
   PubMed Web of Science ®Google Scholar
• Pratt VM, Del Tredici AL, Hachad H, et al. (2018). Recommendations for clinical CYP2C19 genotyping allele selection: a report of the association for molecular pathology. J Mol Diagn 20:269–76.
   PubMed Web of Science ®Google Scholar
• Remmer H, Schenkman J, Estabrook RW, et al. (1966). Drug interaction with hepatic microsomal cytochrome. Mol Pharmacol 2:187–90.
   PubMed Web of Science ®Google Scholar
• Romkes M, Faletto MB, Blaisdell JA, et al. (1991). Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 30:3247–55.
   PubMed Web of Science ®Google Scholar
• Shih C, Museth AK, Abrahamsson M, et al. (2008). Tryptophan-accelerated electron flow through proteins. Science 320:1760–2.
   PubMed Web of Science ®Google Scholar
• Sim SC, Risinger C, Dahl ML, et al. (2006). A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–13.
   PubMed Web of Science ®Google Scholar
• Wang H, An N, Wang H, et al. (2011a). Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation. Drug Metab Dispos 39:830–7.
   PubMed Web of Science ®Google Scholar
• Wang H, Kim RA, Sun D, et al. (2011b). Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay. Xenobiotica 41:826–35.
   PubMed Web of Science ®Google Scholar
• Wang JF, Wei DQ, Chen C, et al. (2008). Molecular modeling of two CYP2C19 SNPs and its implications for personalized drug design. Protein Peptide Lett 15:27–32.
   PubMed Web of Science ®Google Scholar
• Xiao ZS, Goldstein JA, Xie HG, et al. (1997). Differences in the incidence of the CYP2C19Polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rareCYP2C19 mutant allele. J Pharmacol Exp Ther 281:604–9.
   PubMed Web of Science ®Google Scholar